196 related articles for article (PubMed ID: 27899803)
21. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
22. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
23. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
[TBL] [Abstract][Full Text] [Related]
24. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fu J; Heinrichs J; Yu XZ
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
[TBL] [Abstract][Full Text] [Related]
25. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
Martini DJ; Chen YB; DeFilipp Z
Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
27. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
28. Assessing response of therapy for acute and chronic graft-versus-host disease.
Goldberg JD; Giralt S
Expert Rev Hematol; 2013 Feb; 6(1):103-7. PubMed ID: 23373785
[TBL] [Abstract][Full Text] [Related]
29. Chronic graft-versus-host disease.
Lee SJ; Vogelsang G; Flowers ME
Biol Blood Marrow Transplant; 2003 Apr; 9(4):215-33. PubMed ID: 12720215
[TBL] [Abstract][Full Text] [Related]
30. Colonic graft-versus-host disease.
Ross WA; Couriel D
Curr Opin Gastroenterol; 2005 Jan; 21(1):64-9. PubMed ID: 15687887
[TBL] [Abstract][Full Text] [Related]
31. Novel immunosuppression compounds and experimental therapies for chronic graft-versus-host disease.
Michael M; Shimoni A; Nagler A
Acta Haematol; 2013; 130(1):34-43. PubMed ID: 23392110
[TBL] [Abstract][Full Text] [Related]
32. Differential T cell subsets and cytokine profile between steady-state and G-CSF-primed bone marrow and its association with graft-versus-host disease.
León-Rodríguez E; Rivera-Franco MM; Gómez-Martín D; Romo-Tena J; Juárez-Vega G; Merayo-Chalico J; Alcocer-Varela J
Leuk Res; 2017 Dec; 63():47-52. PubMed ID: 29101827
[TBL] [Abstract][Full Text] [Related]
33. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
34. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
35. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
Saidu NEB; Bonini C; Dickinson A; Grce M; Inngjerdingen M; Koehl U; Toubert A; Zeiser R; Galimberti S
Front Immunol; 2020; 11():578314. PubMed ID: 33162993
[TBL] [Abstract][Full Text] [Related]
36. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
37. Janus Kinase Inhibitors and Cell Therapy.
Assal A; Mapara MY
Front Immunol; 2021; 12():740847. PubMed ID: 34531878
[TBL] [Abstract][Full Text] [Related]
38. Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.
Long J; Chang L; Shen Y; Gao WH; Wu YN; Dou HB; Huang MM; Wang Y; Fang WY; Shan JH; Wang YY; Zhu J; Chen Z; Hu J
J Immunol; 2015 Aug; 195(4):1849-57. PubMed ID: 26179902
[TBL] [Abstract][Full Text] [Related]
39. Acute and chronic skin graft-versus-host disease--pathophysiological aspects.
Socié G; Peffault de Latour R; Bouziz JD; Rybojad M
Curr Probl Dermatol; 2012; 43():91-100. PubMed ID: 22377923
[TBL] [Abstract][Full Text] [Related]
40. PIAS3 suppresses acute graft-versus-host disease by modulating effector T and B cell subsets through inhibition of STAT3 activation.
Lee SH; Moon SJ; Park MJ; Kim EK; Moon YM; Cho ML
Immunol Lett; 2014 Jul; 160(1):79-88. PubMed ID: 24718277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
